Bulgaria vs Sao Tome and Principe: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Bulgaria
86.0%
in 2025
Sao Tome and Principe
86.0%
in 2025
Bulgaria rank
92nd
Sao Tome and Principe rank
92nd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Bulgaria
- Sao Tome and Principe
How they compare
Bulgaria currently reports 86.0% against 86.0% in Sao Tome and Principe, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Sao Tome and Principe ahead.
Bulgaria ranks 92nd and Sao Tome and Principe ranks 92nd of 194 countries.
Across the 3 decades both report, Bulgaria averaged higher in 1 and Sao Tome and Principe in 1.
Head to head by decade
| Decade | Bulgaria | Sao Tome and Principe | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 89.1% | 66.9% | 22.2% | Bulgaria |
| 2020s | 87.0% | 90.5% | 3.5% | Sao Tome and Principe |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Bulgaria or Sao Tome and Principe?
- Bulgaria, at 86.0% against 86.0% in Sao Tome and Principe as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Bulgaria and Sao Tome and Principe?
- 0.0%, with Bulgaria ahead.
- How many years of comparable data are there for Bulgaria and Sao Tome and Principe?
- 18 years are reported by both, from 2008 to 2025.
- How do Bulgaria and Sao Tome and Principe rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Bulgaria ranks 92nd and Sao Tome and Principe ranks 92nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.